More than 50 years of experience.
Our goal is to provide Innovative, Affordable pharmaceutical/ biopharmaceutical products for the needy patients in an emerging country with low to medium socio-economic standard.
Minapharm, headquartered in Cairo, is among the leading prescription medicine companies in Egypt and the Middle East.
The last decade was more towards simple pharmaceutical molecules. Currently & in the near future more complex proteins are dedicated for the treatment of more complex diseases; these entities are more complicated in structure.
• Early Embarking on Biogenetic engineering … Using State-of-the-art technology:
Accordingly, the strategy of Minapharm since decades was based on the early embarking on the concept of bridging or fusion of pharma and biopharma. In this region of the world- the first in its kind adopting the concept “from the gene to the protein”. (Using state of the art tech + attachments) (FUSION FOLDER, image no. 2) The company specializes in the manufacture and marketing of innovative specialty pharmaceuticals and through its subsidiary Rhein Minapharm Biogenetics, in the research, development and manufacturing of biopharmaceuticals.
• Acquisition of a leader in R&D … A strong international force in the sector of Biopharma:
The Acquisition of Probiogen (a top ranked German biotech company) was considered as the first acquisition in the World of a leading European biotechnology company by an Egyptian pharma company belonging to the emerging markets. (QUALITY & R&D folder, image no. 3, 4, 5, 6, 7, 7- ) & http://www.probiogen.de
• Leadership; Originally Pharmaceutical:
Our strategic multi-alliances with world leaders in their specialties is the basis of our regional leadership: probably the fastest growing producer of prescription drugs in the region, an exceptionally strong financial position, leaders recognized for innovative thinking & robust market presence.
• How do i want to be perceived in the marketplace?
• Who are my top 3 competitors?